Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Kabos

Showing results (81-90 of 97) with videos related to

Pageof 10
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2020
ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain MetastasesPriya Kumthekar, Shou-Ching Tang, Andrew J Brenner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2025
Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor Positive, HER2 Negative Advanced Breast CancerRobert Wesolowski, Hope S Rugo, Jennifer M Specht, et al.
Frontiers in Oncology|November 23, 2017
Development of Novel Patient-Derived Xenografts from Breast Cancer Brain MetastasesMaría J Contreras-Zárate, D Ryan Ormond, Austin E Gillen, et al.
Nature Communications|May 28, 2026
Brain FGF2 and NCAM1 contribute to FGFR1-dependent progression of estrogen receptor-positive breast cancer brain metastasesMorgan S Fox, Jenny A Jaramillo-Gómez, R Alejandro Marquez-Ortiz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2019
Combination of Trastuzumab Emtansine and Stereotactic Radiosurgery Results in High Rates of Clinically Significant Radionecrosis and Dysregulation of Aquaporin-4Priscilla K Stumpf, Diana M Cittelly, Tyler P Robin, et al.
Breast Cancer Research : BCR|August 4, 2018
A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancerJennifer R Diamond, S G Eckhardt, Todd M Pitts, et al.
Hormones & Cancer|July 26, 2017
The Androgen Receptor Supports Tumor Progression After the Loss of Ovarian Function in a Preclinical Model of Obesity and Breast CancerElizabeth A Wellberg, L Allyson Checkley, Erin D Giles, et al.
Nature Communications|December 22, 2015
The Six1 oncoprotein downregulates p53 via concomitant regulation of RPL26 and microRNA-27a-3pChristina G Towers, Anna L Guarnieri, Doug S Micalizzi, et al.
NPJ Breast Cancer|October 5, 2024
Clinical and immune responses to neoadjuvant fulvestrant with or without enzalutamide in ER+/Her2- breast cancerAnthony D Elias, Alyse W Staley, Monica Fornier, et al.
JCI Insight|July 27, 2018
FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivationElizabeth A Wellberg, Peter Kabos, Austin E Gillen, et al.
Pageof 10

Showing results (81-90 of 97) with videos related to

Sort By:
Pageof 10
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2020
ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain MetastasesPriya Kumthekar, Shou-Ching Tang, Andrew J Brenner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2025
Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor Positive, HER2 Negative Advanced Breast CancerRobert Wesolowski, Hope S Rugo, Jennifer M Specht, et al.
Frontiers in Oncology|November 23, 2017
Development of Novel Patient-Derived Xenografts from Breast Cancer Brain MetastasesMaría J Contreras-Zárate, D Ryan Ormond, Austin E Gillen, et al.
Nature Communications|May 28, 2026
Brain FGF2 and NCAM1 contribute to FGFR1-dependent progression of estrogen receptor-positive breast cancer brain metastasesMorgan S Fox, Jenny A Jaramillo-Gómez, R Alejandro Marquez-Ortiz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2019
Combination of Trastuzumab Emtansine and Stereotactic Radiosurgery Results in High Rates of Clinically Significant Radionecrosis and Dysregulation of Aquaporin-4Priscilla K Stumpf, Diana M Cittelly, Tyler P Robin, et al.
Breast Cancer Research : BCR|August 4, 2018
A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancerJennifer R Diamond, S G Eckhardt, Todd M Pitts, et al.
Hormones & Cancer|July 26, 2017
The Androgen Receptor Supports Tumor Progression After the Loss of Ovarian Function in a Preclinical Model of Obesity and Breast CancerElizabeth A Wellberg, L Allyson Checkley, Erin D Giles, et al.
Nature Communications|December 22, 2015
The Six1 oncoprotein downregulates p53 via concomitant regulation of RPL26 and microRNA-27a-3pChristina G Towers, Anna L Guarnieri, Doug S Micalizzi, et al.
NPJ Breast Cancer|October 5, 2024
Clinical and immune responses to neoadjuvant fulvestrant with or without enzalutamide in ER+/Her2- breast cancerAnthony D Elias, Alyse W Staley, Monica Fornier, et al.
JCI Insight|July 27, 2018
FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivationElizabeth A Wellberg, Peter Kabos, Austin E Gillen, et al.
Pageof 10